RB1 and pancreatic neoplasm: Significantly, median sensitivity in the RB1-defective group was comparable to that of the pancreatic cancer line CAPAN1, known for profound PARPi sensitivity due to defective BRCA225 that we included to benchmark clinically relevant response levels.